WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Tuesday, July 23, 2013

L-DOPA INCREASES THE RISK OF NEUROPATHY

14th July 2013 - New research
 
Movement Disorders [2013] Jul 8 [Epub ahead of print] (R.Ceravolo, G.Cossu, M.B.di Poggio, L.Santoro, P.Barone, M.Zibetti, D.Frosini, V.Nicoletti, F.Manganelli, R.Iodice, M.Picillo, A.Merola, L.Lopiano, A.Paribello, D.Manca, M.Melis, R.Marchese, P.Borelli, A.Mereu, P.Contu, G.Abbruzzese, U.Bonuccelli) 

L-dopa has been found to increase the risk of neuropathy. Neuropathy is a collection of medical disorders that occur when nerves of the peripheral nervous system are damaged by various means.
Motor nerve damage leads to symptoms such as muscle weakness, cramps, spasms, a loss of balance and coordination. People may find it difficult to walk, feel like they have heavy legs, stumble, or tire easily. Damage to arm nerves may make it difficult to do routine tasks like carry bags, open jars, or turn door knobs. Sensory nerve damage can cause tingling, numbness, pinching and pain. Autonomic nerve damage can lead to abnormal blood pressure and heart rate, reduced ability to perspire, constipation, bladder dysfunction, diarrhea, incontinence, sexual dysfunction, and thinning of the skin. For more information go to Neuropathy. 
Those people taking L-dopa for more than 3 years were most affected with nearly 20% of them being diagnosed with neuropathy. Only 7% of those people taking L-dopa for less than three years were diagnosed with neuropathy. The risk of neuropathy was not influenced by : Parkinson's Disease duration, severity of Parkinson's Disease or gender. The risk of neuropathy increased by approximately 8% for each year of age. The L-dopa dosages were higher in those affected. So L-dopa dosage and duration and age were the main risk factors for neuropathy. 

THE EFFECT OF PHYSIOTHERAPY ON PARKINSON'S DISEASE

11th July 2013
Neurologia i Neurochirurgia Polska [2013] 47 (3) : 256-262 (J.Cholewa, M.Boczarska-Jedynak, G.Opala) 


The aim of this study was to evaluate the influence of movement rehabilitation on the severity of motor symptoms in Parkinson's Disease. Patients took part in one hour  rehabilitation exercises twice a week, which were aimed at increasing movement ranges, balance improvement, movement agility and walking. Patients' clinical status was assessed with the major Parkinson's Disease symptom score (the Unified Parkinson's Disease Rating Scale (UPDRS) parts I-III). Activity of daily living was evaluated with the Schwab and England scale. The quality of life was evaluated by the Parkinson's Disease Questionnaire (PDQ-39).
The main emphasis was placed on the ability to cope with daily activities. A significant difference in scores on the given scales was observed before and after the 12-week assessment period. Parkinson's Disease symptom score (UPDRS part I) improved by 17%, part II improved by 22%, part III improved by 19%, and PDQ-39 score improved by 17%. Mean score of the Schwab and England scale improved by 9%, indicating an improved quality of life. The rehabilitation programme clearly improved the severity of motor symptoms in people with Parkinson's Disease. 

THE MODIFIED RANKIN SCALE FOR ASSESSING PARKINSON'S DISEASE

7th July 2013
 
Journal of Clinical Neuroscience [2013] Jun 26 [Epub ahead of print] (T.Simuni, S.T.Luo, K.L.Chou, H.Fernandez, B.He, S.Parashos) 
An exploratory analysis was conducted in to the use of the modified Rankin Scale (mRS) as a global measure of disability in early Parkinson's Disease. For more information go to the Modified Rankin Scale The mRS assesses the level of disability caused by neurological disorders. It is scored 0-6 with lower scores reflecting less disability.
1 No symptoms                                                                                                                                                           1 - No significant disability : Able to carry out all usual activities, despite some symptoms. 
2 - Slight disability : Able to look after own affairs without assistance, but unable to carry out all previous activities. 
3 - Moderate disability : Requires some help, but able to walk unassisted. 
4 - Moderately severe disability : Unable to attend to bodily needs without assistance. Unable to walk unassisted. 
5 - Severe disability : Requires constant nursing care and attention, bedridden, incontinent. 
6 - Dead
The association of the Modified Rankin Scale was compared with Parkinson's Disease related assessments : the Unified Parkinson Disease Rating Scale (UPDRS), cognitive function characterized by the Symbol Digit Modalities - verbal, Scales for Outcomes in Parkinson's disease - cognition (SCOPA-COG), quality of life (Parkinson's disease questionnaire (PDQ-39), EuroQOL,  Beck Depression Inventory II (BDI), and Total Functional Capacity (TFC). All of the measures except SCOPA-COG had a significant association with the modified Rankin Scale thereby demonstrating its significance to Parkinson's Disease.

Wednesday, July 17, 2013

Top-Ranked Hospitals for Neurology & Neurosurgery

Too many to list. Please click on the following:


http://health.usnews.com/best-hospitals/rankings/neurology-and-neurosurgery


The number one:

National RankHospitalU.S. News Score
#1
Baltimore, MD
100.0 / 100





 
#2
                          Mayo Clinic                                                98.6 / 100                                 
                         Rochester, MN

Monday, July 8, 2013

What you need to know about Parkinsonism Pugilistica: The Punch Drunk Syndrome

 Release date: 7/8/2013

A new television series appearing on Showtime, Ray Donovan, includes a character who exhibits Parkinsonian symptoms. The show attributes this to the character's past career as a boxer. Do you know the difference between Parkinson's disease and Parkinsonism Pugilistica? Dr. Michael S. Okun, NPF's National Medical Director, explains that and more in this special NPF statement.


What is Parkinsonism Pugilistica?
In the 1920’s a pathologist named Harrison Martland described, in a classical article published in theJournal of the American Medical Association (JAMA), a syndrome that was associated with repeated head injury particularly within former boxers.  Many physicians and scientists followed this seminal report over the ensuing decades by better characterizing this syndrome, and importantly by clarifying that it can occur in anyone with repeated head trauma.  The most important finding was that it was not exclusive to boxers.  The potential symptoms included memory problems, behavioral issues, paranoia, and other features such as hallucinations.  In cases where the predominant symptoms were related to thinking or behavior, the term Dementia Pugilistica was used, although some people have coined the term “punch drunk” to describe the behavioral features.  Punch drunk was also a term used in Martland’s original description.  In cases wheretremor, stiffness, slowness, walking problems, or balance issues dominated the clinical picture, the term Parkinsonism Pugilistica has been utilized.  The syndrome should however, not be confused with regular Parkinson’s disease, which is a slowly progressive neurodegenerativedisorder associated with motor and non-motor symptoms.  Regular Parkinson’s disease, unlike Dementia and Parkinsonism Pugilistica, is responsive to dopaminergic therapies.
What is the difference between Parkinsonism Pugilistica and regular Parkinson’s disease?
Parkinsonism pugilistica is thought to occur as a result of repeated blows to the head, and in some cases can result from multiple bad concussions.  Most cases of the syndrome have been referred to in the scientific literature as Dementia Pugilistica.  It is somewhat rare to observe the classical parkinsonian features of regular Parkinson’s disease associated with this head trauma related syndrome.  It is possible however, to observe some overlap symptoms (tremor, stiffness, slowness, walking issues) with the behavioral features.  The pattern and temporal occurrence of cognitive problems, and also the poor response to dopaminergic therapy can help one to distinguish Parkinsonism Pugilistica from regular Parkinson’s disease.  One should not assume that just because a person was a past boxer that they suffer from Dementia or Parkinsonism Pugilistica, or both.
How are Parkinson’s disease and Parkinsonism Pugilistica related to head trauma?
There are a number of epidemiological studies that have linked Parkinson’s disease risk to a history of head trauma.  If you already suffer from Parkinson’s disease, you should not worry too much about these large association type studies, as the treatment is the same for regular Parkinson’s disease, with or without a history of head trauma.
Parkinsonism Pugilistica can result from repeated blows to the head, regardless of the source of the impacts; it does not only affect boxers.  Recently, much press has been given to former NFL players, especially those with repeated head trauma, and coincident symptoms of Dementia and Parkinsonism Pugilistica.  Athletes from other sports, such as hockey, have also shown signs of Dementia and Parkinsonism Pugilistica.  It is important to keep in mind that in some cases have not been due to Dementia or Parkinsonism Pugilistica despite similar symptoms. .
Selected References:
  1. Jordan BD. The clinical spectrum of sport-related traumatic brain injury. Nat Rev Neurol. 2013 Apr;9(4):222-30. doi: 10.1038/nrneurol.2013.33. Epub 2013 Mar 12. PubMed PMID: 23478462.
  2. Gavett BE, Stern RA, McKee AC. Chronic traumatic encephalopathy: a potential late effect of sport-related concussive and subconcussive head trauma. Clin Sports Med. 2011 Jan;30(1):179-88, xi. doi: 10.1016/j.csm.2010.09.007. Review. PubMed PMID: 21074091; PubMed Central PMCID: PMC2995699.
  3. McKee AC, Cantu RC, Nowinski CJ, Hedley-Whyte ET, Gavett BE, Budson AE, Santini VE, Lee HS, Kubilus CA, Stern RA. Chronic traumatic encephalopathy in athletes: progressive tauopathy after repetitive head injury. J Neuropathol Exp Neurol. 2009 Jul;68(7):709-35. doi: 10.1097/NEN.0b013e3181a9d503. Review. PubMed PMID: 19535999; PubMed Central PMCID: PMC2945234.
  4. Jordan BD. Chronic traumatic brain injury associated with boxing. Semin Neurol. 2000;20(2):179-85. Review. PubMed PMID: 10946737.
  5. Mendez MF. The neuropsychiatric aspects of boxing. Int J Psychiatry Med. 1995;25(3):249-62. Review. PubMed PMID: 8567192.
  6. BRANDENBURG W, HALLERVORDEN J. [Dementia pugilistica with anatomical findings]. Virchows Arch. 1954;325(6):680-709. German. PubMed PMID: 13226712.
  7. Martland HS (1928). "Punch Drunk". Journal of the American Medical Association 91 (15): 1103–1107. doi:10.1001/jama.1928.02700150029009


Friday, July 5, 2013

THE EFFECT OF DEEP BRAIN STIMULATION (DBS) ON PARKINSON'S DISEASE

4th July 2013 - New research

Ideggyogy Sz. [2013] 66 (3-4) : 115-120 (G.Tamás, A.Takáts, P.Radics, I.Rózsa, E.Csibri, G.Rudas, P.Golopencza, L.Entz, D.Fabó, L.Eross) 
Researchers assessed the effect of Deep Brain Stimulation (DBS) on the different types of symptoms experienced in Parkinson's Disease. Deep Brain Stimulation  (DBS) involves the use of electrodes that are implanted into the brain and connected to a small electrical device called a pulse generator that can be externally programmed. DBS requires careful programming of the stimulator device.
The major Parkinson's Disease symptom score (the Unified Parkinson's Disease Rating Scale) decreased by 70%. Patient condition improved according to the Hoehn-Yahr scale, approximately by two stages. Twelve hours after the withdrawal of Parkinson's Disease drugs execution of daily activity improved by 57% and motor functions developed by 79%. Duration of dyskinesias decreased by 62%. Duration of akinesia (loss of movement) diminished by 87%. Quality of life rose by 41%. Neuropsychological tests detected improvement in verbal memory. The dosage of Parkinson's Disease drugs could be reduced by 63% after the operation had been completed.

They concluded that, with Deep Brain Stimulation and by careful patient selection, the dosage of Parkinson's Disease drugs could be significantly reduced with considerable improvements in motor function and quality of life.

RASAGILINE'S EFFECT ON TREMOR IN PARKINSON'S DISEASE

24th June 2013 - New research

The International Journal of Neuroscience [2013] Jun 17 [Epub ahead of print] (M.F.Lew)
Researchers reviewed the effects on tremor in Parkinson's Disease of 1mg daily oral rasagiline, on its own and with other treatments. Tremor is a common symptom of Parkinson's Disease, but it is less responsive to dopaminergic therapy than are the symptoms of bradykinesia and rigidity. Rasagiline is a MAO inhibitor that is marketed as Azilect.  
Of 22 identified publications, 2 large placebo-controlled trials of rasagiline monotherapy (TEMPO and ADAGIO) and 2 large placebo controlled trials of rasagiline with L-dopa (PRESTO and LARGO) specifically evaluated the effect of rasagiline on tremor using the Unified Parkinson's Disease Rating Scale (UPDRS). Analysis of these studies showed rasagiline on its own significantly improved tremor in early Parkinsons' Disease independently of disease duration.
In people taking L-dopa who had motor fluctuations who were already receiving optimal dopaminergic treatment, the addition of rasagiline significantly improved their tremor. Significant improvement was evident as early as ten weeks from the initiation of the use of rasagiline. Tremor symptoms also improved in people with severe tremor when rasagiline was added to their existing Parkinson's Disease treatments. The researchers contend that the data suggest that rasagiline used on its own or alongside other treatments is effective for reducing tremor severity in people with Parkinson's Disease.

Link between allergic rhinitis and Parkinson’s disease

Kriss Moore
The Almagest - People who have allergic rhinitis have three times the risk of Parkinson’s disease. Previous research has shown that those taking non-steroidal anti-inflammatory drugs, like ibuprofen, are less likely to develop Parkinson’s disease. So researchers at the Mayo Clinic set out to find out more about a possible link between inflammation and Parkinson’s disease. They studied 196 people who had Parkinson’s disease and compared them with a group of similar age and gender who did not.

Those with allergic rhinitis – or hayfever, an inflammatory condition – were 2.9 times more likely to develop Parkinson’s disease. But no similar link was seen for other inflammatory diseases like lupus, rheumatoid arthritis or vitiligo. This may be because there were only small numbers of participants who had these conditions. The researchers say that those with allergic rhinitis exert an immune response to allergens which could affect the brain, leading to Parkinson’s disease. The study does not establish that allergies cause Parkinson’s disease, just that there is an association. Hopefully future research will lead to ways of blocking any inflammation that does cause Parkinson’s disease.

Wednesday, June 19, 2013

SWEETENER FOR TREATING PARKINSON'S DISEASE

19th June 2013 - New research

Journal of Biological Chemistry [2013] 288 (24) : 17579-17588 (R.Shaltiel-Karyo, M.Frenkel-Pinter, E.Rockenstein, C.Patrick, M.Levy-Sakin, A.Schiller, N.Egoz-Matia, E.Masliah, D.Segal, E.Gazit)  
The sweetener, mannitol, has been proposed as a potential means of treating Parkinson's Disease because of the dual mechanisms it has in the brain. Mannitol, which is used in medicine, is derived from mannose, which is a sugar. For more information go to Mannitol.
Researchers assessed the ability of mannitol to (1) interfere with the aggregation of alpha-synuclein, and (2)  its ability to disrupt the blood-brain barrier. Alpha-synuclein can accumulate in the brains of people with Parkinson's Disease and other medical disorders but can also be absent in Parkinson's Disease. It therefore appears that Parkinson's Disease can cause alpha-synuclein rather than alpha-synuclein being the cause of Parkinson's Disease as is often claimed. The blood brain barrier restricts access to the brain to certain substances. They demonstrated the effect of mannitol on alpha-synuclein by various means, and a decrease in alpha-synuclein accumulation.

The researchers therefore suggest mannitol as a basis for a dual mechanism therapeutic agent for the treatment of Parkinson's Disease. However, the research was  only carried out on mice and flies, who did not have Parkinson's Disease and who were not rid of its symptoms.

THE EFFECT OF PRAMIPEXOLE ON PARKINSON'S DISEASE

13th June 2013 - New research

Lancet Neurology [2013] May 30 [Epub ahead of print] (A.H.Schapira, M.P.McDermott, P.Barone, C.L.Comella, S.Albrecht, H.H.Hsu, D.H.Massey, Y.Mizuno, W.Poewe, O.Rascol, K.Marek)  
The Pramipexole On Underlying Disease (PROUD) study was designed to identify whether or not early versus delayed pramipexole initiation has clinical benefits in people with Parkinson's Disease. Pramipexole, which is sold as Mirapex, Mirapexin and Sifrol, is a dopamine agonist used for treating early-stage Parkinson's Disease. For more information go to Mirapex.

People taking pramipexole were given 1.5mg pramipexole per day. The average difference in Parkinson's Disease symptom scores (the UPDRS) showed no significant difference between early and delayed pramipexole. Fifteen months of use showed no benefit when compared to the use of pramipexole being delayed for 6 to 9 months. Over 80% of people who took pramipexole reported adverse events, with 81% of those given early pramipexole and 84% of those given delayed pramipexole. The most frequent adverse event was nausea.  Serious adverse events were reported by 10% of people in the early pramipexole group and 8% in the delayed pramipexole group. The authors conclude that the results do not support the hypothesis that pramipexole has disease-modifying effects.